which are responsible for the regulation of ovarian and testicular functions (Cheung & Wong, 2008; Sealfon, Weinstein, & Millar, 1997; Stojilkovic & Catt, 1995) .
The secretion of GnRH is regulated by Kisspeptin (Kiss1) (Funes et al., 2003; Seminara et al., 2003) . By acting through its G-protein coupled receptor, Kiss1-R, Kiss1 centrally stimulates pulsatile GnRH release (Funes et al., 2003; Seminara et al., 2003) . Kiss1 and its receptor were also found in human and rat ovarian tissues, as well as in granulosa-lutein cells in vitro (Cejudo Roman et al., 2012; Gaytan et al., 2009) . Also, the presence of GnRH-R transcripts was confirmed in ovarian follicles and corpus luteum (CL), for example in mouse (Torrealday, Lalioti, Guzeloglu-Kayisli, & Seli, 2013) and human (Choi, Gilks, Auersperg, & Leung, 2006) . Thus, functional interactions between these two systems, that is GnRH and Kiss, within the ovary have been implicated.
Long-term release GnRH analogs are synthetic compounds that interact and stimulate GnRH-R. After an initial sudden increase (i.e., flare-up) effect upon binding to the receptor, the sustained action of GnRH or its agonists (GnRH-a) causes GnRH-R downregulation. The inhibitory actions of GnRH and/or GnRH-a on gonadal steroidogenesis involve suppression of gonadotropin receptors or intermediary enzymes involved in steroidogenic pathways in the ovary, for example P450scc enzyme, 3β-hydroxysteroid dehydrogenase (3βHSD) or aromatase (Clayton, Harwood, & Catt, 1979; Janssens et al., 2000; Khosravi & Leung, 2003; Sridaran, Philip et al., 1999) . In some reports, GnRH-a were suggested to suppress expression of FSH and LH receptors (Guerrero, Stein, Asch, de Fried, & Tesone, 1993; Tilly, LaPolt, & Hsueh, 1992) , and to decrease gonadotropin-induced cAMP levels or the activities of steroidogenic factors such as steroidogenic acute regulatory (STAR) protein (Shinohara, Knecht, & Catt, 1985; Sridaran, Philip et al., 1999) . The presence of both GnRH and the GnRH-R in the extrapituitary tissues implies an autocrine/paracrine role for GnRH and a potential site of action for GnRH-a (Aguilar-Rojas & HuertaReyes, 2009 ).
With regard to the dog, only one GnRH isoform (GnRH-I) and one receptor type have been identified in reproductive tissues so far, and their spatial and temporal expression in canine uterus and placenta have been described recently .
Similar to other mammals, also in the dog, GnRH by acting centrally modulates both inhibitory and stimulatory responses affecting ovarian function and regulating cyclicity (reviewed in (Gobello, 2007) ).
Importantly, however, with respect to canine luteal function, neither LH nor GnRH seems to be mandatory at the early luteal stage (Onclin, Verstegen, & Concannon, 2000) . Instead, prostaglandins (PGs) produced locally, that is within the CL, and in particular PGE2, appear to be the main luteotrophic factors involved in establishment of luteal function (reviewed in (Kowalewski, 2014) ). Concerning the luteotrophic effect of PGE2, it was found to induce progesterone (P4) output in lutein cells in vitro (Kowalewski, Fox, Gram, Boos, & Reichler, 2013) . Similarly, interfering with cyclooxygenase 2 (COX2, PTGS2) in vivo with its specific inhibitor (firocoxib, Previcox, Merial) decreases STAR and 3βHSD mRNA and protein expression .
Despite recent progress in understanding canine luteal physiology in pregnant and non-pregnant cycles (Kowalewski, 2012 (Kowalewski, , 2014 Kowalewski et al., 2015) , the mechanisms of suppression and resumption of ovarian activity and, subsequently, luteal function after short/ long-term inhibition of gonadal activity remains poorly understood.
Therefore, the first aim of this study was to investigate the presence of GnRH-R in CL from non-pregnant dogs (days 5, 15, 25, 35, 45 and 65 post-ovulation, p.o.) during the non-pregnant cycle. With this goal, we aimed to establish the basic capability of canine CL to respond to GnRH. Additionally, the expression of GnRH-R, Kiss1, 3βHSD, PGR, STAR, COX2 (PTGS2) , PTGES, EP2 (PTGER2), EP4 (PTGER4) and the VEGF system was investigated at mid-luteal phase following the first oestrus after long-term pre-pubertal GnRH agonist treatment.
| MATERIALS AND METHODS

| Animals, treatments and tissue materials
For Experiment 1, corpora lutea (CL) were collected by routine ovariohysterectomy (OHE) from sexually mature (2-8 years old), healthy, cross-breed, non-pregnant dogs throughout dioestrus at days: 5 (n = 4), 15 (n = 5), 25 (n = 5), 35 (n = 4), 45 (n = 3) and 65 (n = 3) postovulation (p.o.), and were used for assessment of GnRH-R gene expression. Blood plasma P4 concentrations and vaginal cytology were used to determine the cycle stage. P4 levels of at least 5 ng/ml were considered as the day of ovulation (Concannon, McCann, & Temple, 1989) . For RNA preservation, tissue samples were placed in RNAlater (Ambion Biotechnology GmbH, Wiesbaden, Germany) for 24 hr at +4°C and afterwards they were stored at −80°C until total RNA extraction as described previously (Kowalewski, Mason et al., 2006) . For non-radioactive in situ hybridization (ISH), CL were trimmed of surrounding tissues and fixed in 10% neutral phosphate-buffered formalin for 24 hr at +4°C.
In Experiment 2, the effects of pre-pubertal application of the GnRH agonist deslorelin acetate on canine luteal function following the first oestrus were assessed using luteal samples that originated from the same animals as in a previous study (Kaya et al., 2015) . Briefly, thirteen (n=13) healthy, Caucasian shepherd and kangal cross-breed, pre-pubertal bitches aged 4.2 ± 0.6 months with a body weight of 9.5 ± 3.4 kg were used. Implants containing either 9.4 mg (n = 5) or 4.7 mg (n = 4) deslorelin (Suprelorin; Virbac, France), or placebo (sodium chloride 0.9%; n = 4), were administered subcutaneously in the interscapular region using a single-use applicator. The signs of oestrus were monitored once daily by assessing physical (vulvar appearance and swelling, sero-sanguinous vaginal discharge) and sexual behavioural changes, until occurrence of the first oestrus. Vaginal cytology, serum P4 and estradiol-17β (E2) concentrations were measured every other day. No clinically detectable systemic side effects were observed in any of the treated bitches. Control and those animals that showed oestrous signs were subjected to OHE during the mid-luteal phase (days 30-45) and mature corpora lutea (CL) were collected. The onset of puberty appears quite variable within several small and large breeds of dogs. While many smaller breeds reach puberty between 6 and 10 months of age, in some larger breed bitches, onset of the first oestrous cycle is seen at 2 years of age (England & Heimendahl, 2010; Root Kustritz, 2010) . Accordingly, as reported previously (Kaya et al., 2015) , control animals used in our study showed oestrus within 61.9 ± 9.7 weeks after placebo treatment. Four (n = 4) of the deslorelin-treated bitches (n = 2 in each of the implanted groups) came into oestrus during the 82.7 ± 8.9 weeks of observation. The other treated bitches (n = 3 and n = 2 in groups treated with 9.4 mg and 4.7 mg Suprelorin, respectively) did not show oestrus by the end of the observation period at 101.5 weeks when the observation period finished. Consequently, samples from these four dogs, which came into oestrus, were merged into one group for further analyses including semi-quantitative PCR. For mRNA analysis, tissues were 
| RNA isolation and semi-quantitative RT-PCR
From all samples, total RNA was extracted using TRIzol ® -Reagent Table 1 (ordered from Microsynth, Balgach, Switzerland). In addition, canine-specific TaqMan Gene Expression Assays purchased from Applied Biosystems
Kiss1-R (Prod. No. Cf02715933_u1).
| Hormone analysis
Blood samples were centrifuged for 3 min at 3,000 g, and the sera obtained were stored at −18°C until analysis. The concentrations of P4 (ng/ml) and E2 (pg/ml) were measured in serum samples using the electro-chemiluminescence immunoassay (ECLIA) with a fully automated Cobas Modular E170 Analyzer (Roche Diagnostics, Mannheim, Germany) in an internationally certified commercial laboratory (Düzen Laboratories Group, Ankara, Turkey) as described before (Agaoglu et al., 2011) . Extraction efficiency was >95%. The mean intra-and interassay coefficients of variance for P4 were 3.2% and 1.7%, respectively. The analytic sensitivity was 0.03 ng/ml. Values for E2 assay were 5.0 pg/ml (sensitivity), 3.0% (intra-assay coefficient) and 1.7%
(interassay coefficient).
| In situ hybridization (ISH)
A non-radioactive ISH method was carried out to localize GnRH-R mRNA in the canine CL. Total RNA was extracted, and hybridization probes were prepared following the same method used in our previous studies (Kowalewski, Mason et al., 2006) . Briefly, reverse transcription was performed using the following canine-specific primers to prepare (cRNA) probes: GnRH-R forward 5′-CGC CTC TCC TGA ACA GAA TC-3′, GnRH-R, reverse 5′-GTT GGC CAA GGT CAG ATG TT-3′; the amplicon length was 250 bp. The PCR products were separated on ethidium bromide-stained 2% agarose gels, then isolated using the Qiaex II gel extraction system (Qiagen GmbH Hilden, Germany) and subcloned into the pGEM-T vector (Promega, Duebendorf, Switzerland). Incorporation of selected genes in the pGEM-T vector was proved by control digestion with NcoI and NotI restriction enzymes (New England Biolabs, Frankfurt, Germany) and sent for commercial sequencing (Microsynth, Balgach, Switzerland). Afterwards, pGEM-T vectors were linearized with the restriction enzymes NcoI and NotI, for antisense cRNA and sense cRNA, respectively. Hybridization probes were prepared using the DIG-RNA labelling kit according to the manufacturer's protocols (Roche Diagnostics, Mannheim, Germany). Then, cRNA probes were applied to each section and incubated overnight at 37°C for hybridization. Afterwards, hybridized probes were detected with alkaline phosphatase-conjugated, sheep anti-DIG Fab Fragments (Roche Diagnostics) diluted 1:5,000, and signals were visualized using the substrate 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (NBT/BCIP; Roche Diagnostics).
No counterstaining was applied.
| Statistical analysis
GraphPad version 3.06 software (GraphPad Software, Inc., San Diego, California, USA) was used to assess differences in target gene expression.
Statistical analysis was performed using either the Kruskal-Wallis test 
| RESULTS
| Hormonal profiles
No significant differences were observed for P4 and E2 concentrations between treated and control animals at the time of tissue collection (p > .05, Figure 1 ).
| Localization of canine GnRH-R mRNA and its expression in canine CL throughout the luteal phase in non-pregnant dogs
Although generally low, GnRH-R expression was time dependent in non-pregnant dogs CL throughout the luteal phase (p < .0001). The highest expression was detected at the beginning of the luteal phase, at days 5 and 15 p.o.. This was followed by a significant decrease (Figure 2a ).
To localize GnRH-R-mRNA, non-radioactive ISH was performed during the early luteal stage when its expression was at the highest relative mRNA levels. Specific signals were targeted to luteal cells (Figure 2b ). No background staining was observed in negative controls (sense probes) (Figure 2c ).
| Effects of deslorelin treatment on luteal gene expression at mid-dioestrus
Whereas the expression of STAR did not differ significantly (p = .09) between the two groups (i.e., treated versus non-treated), the expression of 3βHSD was higher (p = .03) in deslorelin-treated animals ( Figure 3 ). As for genes encoding for the PG system, the expression of COX2 (PTGS2) and PTGES was not affected by the treatment (p = .6
and p = .2, respectively). Expression of the two PGE2 receptors was affected in CL of treated dogs, showing opposite effects: EP2 was significantly higher in treated animals (p = .04), while EP4 expression was lower in that group (p = .04) (Figure 3 ). With regard to angiogenic factors of the VEGF family, only the expression of VEGFR1 was affected significantly (p = .04) and was elevated in CL of deslorelin-treated animals, whereas VEGFA and VEGRF2 did not differ (p = .1 and p = .6, respectively) (not shown).
Expression of the following genes did not differ between the two groups: Kiss1-R (p = .3), PRLR (p = .2), PGR (p = .9), ERα (p = .08) and
In both deslorelin-treated and control dogs, the relative expression of GnRH-R and Kiss1 was low and in some samples below the detection limits, preventing us from performing statistical analysis.
| DISCUSSION
In addition to its well-known properties in regulating the mammalian pituitary gland, and thereby, reproductive function, the GnRH system exerts many paracrine, autocrine and endocrine actions in numerous , 2015) and breast (Cheung & Wong, 2008) . While the role of this system in ovarian steroidogenesis (Sridaran, Lee et al., 1999; Sridaran, Philip et al., 1999) and apoptosis Sridaran, Hisheh, & Dharmarajan, 1998; Sridaran, Lee et al., 1999; Sridaran, Philip et al., 1999) has been demonstrated in several mammalian species, there is still a lack of information regarding its possible functions in the domestic canine species. Therefore, here, first we attempted to show the basic capability of canine CL to F I G U R E 3 Expression of selected target gene mRNAs as determined by real-time (TaqMan) PCR in luteal samples collected from deslorelin-treated and control dogs following the first oestrus. Numerical data are presented as geometric means (Xg) ± geometric standard deviation (SD). Bars with different asterisks (*, **) denote the significant differences between two groups, i.e., p=.03 for 3B-HSD and, p=.04 for EP2 and EP respond directly to GnRH, by investigating the mRNA expression of its receptor GnRH-R during the non-pregnant cycle (days 5, 15, 25, 35, 45 and 65 post-ovulation).
Indeed, although generally low, the transcripts encoding for
GnRH-R were detectable in luteal samples throughout the nonpregnant cycle. There was a gradual decrease towards the mid-luteal phase, and further downregulation was seen at the late luteal stage. A similar expression pattern of GnRH-R was also described for the pregnant rat ovary, where progression of the luteal phase was associated with diminishing expression of immunoreactive GnRH-R . As detected by ISH, GnRH-R mRNA was localized in luteal cells, matching similar expression pattern of GnRH-R in other mammalian species, for example monkey and rabbit (Zerani et al., 2010) . Therefore, our findings imply possible regulatory involvement of GnRH within the canine CL.
This is supported by the presence of detectable amounts of Kiss1-R in canine CL. The relative importance of locally expressed GnRH-R for canine luteal physiology remains, however, to be investigated further.
Hormonal approaches to postpone or prevent the onset of cyclicity in dogs are being explored. In contrast to its natural pulsatile hypothalamic secretion, continuous exogenous administration of a GnRH agonist results in downregulation of the GnRH receptors and desensitization of the pituitary gonadotrophs (Finch, Caunt, Armstrong, & McArdle, 2009) . Furthermore, suppression of LH and FSH levels and gonadal steroidogenic activity is observed, thereby blocking reproductive function (Rubion et al., 2006; Trigg et al., 2001) . Therefore, in recent years, GnRH analogs have been developed as a non-surgical method to control reproduction in dogs, as well as in cats (Kutzler & Wood, 2006; Trigg et al., 2001) .
The knowledge about the application of GnRH agonists in females is, however, still not fully established, mostly due to the "flare-up" effect they may cause on the pituitary-gonadal axis. In a previous study utilizing the same animals (Kaya et al., 2015) , the effects of deslorelin implants on epiphyseal closure, body development and time to onset of puberty were investigated. It has been clearly demonstrated that deslorelin could be used efficiently for delaying puberty in pre-pubertal dogs. Following this line, in the present study, the possible long-term effects of Suprelorin treatment on canine luteal function were assessed by investigating the expression of several factors involved in establishment and maintenance of canine CL following the first oestrus after long-term pre-pubertal treatment. Accordingly, during the early luteal phase, PGs appear to be among the most important factors involved in establishment of luteal function in the dog (Kowalewski et al., 2013) . Afterwards, during luteal maintenance, PRL acts as the main luteotropic factor (Okkens, Bevers, Dieleman, & Willemse, 1990) , with its receptor, PRLR, being upregulated at early-and mid-luteal phase (Kowalewski, Michel et al., 2011) . STAR protein is a key factor regulating the provision of steroidogenic substrates and is one of the main downstream responders in the steroidogenic cascade, the first enzymatic step of which is catalysed by 3βHSD. The expression of both proteins mirrors circulating P4 levels in the dog (Kowalewski & Hoffmann, 2008; Kowalewski, Mason et al., 2006) . Furthermore, establishment of luteal function depends on vascularization, with the VEGF system being the most prominent representative of the entire family of angiogenic and vasoactive factors. This led us to investigate the expression levels of all these important factors in CL from GnRH-treated dogs, enquiring about possible carry-over effects in the following cycle after the postponed onset of oestrus. Whereas COX2 and PTGES remained unaffected, the expression profiles of EP2 and EP4 receptors were changed significantly: whereas EP2 was elevated, EP4 expression was lower in the CL of treated animals. As for EP2, we found increased expression of one of the VEGF receptors, VEGFR1. Interestingly, in contrast to unaffected STAR mRNA levels, we found upregulated levels of 3βHSD in treated animals. However, neither the enhanced expression of EP2 and VEGFR1 nor the elevated levels of 3βHSD were related to increased luteal functionality, as similar P4 and E2 plasma levels were detected in both groups, that is control and treated bitches. We in- 
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